Business Wire

NOVOTECH

28.8.2024 14:06:26 CEST | Business Wire | Press release

Share
Novotech Earns Renewed Certification as an Employer of Choice for Gender Equality

Novotech, a global full-service clinical Contract Research Organization (CRO), proudly announces its continued recognition as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) in 2024. This marks another milestone in Novotech's ongoing commitment to fostering an inclusive and equitable workplace.

The EOCGE certification is a prestigious accolade in Australia's business landscape, acknowledging organizations that demonstrate exceptional dedication to achieving gender equality. This voluntary program recognizes employers who go above and beyond in creating an environment where all employees, regardless of gender, can thrive and succeed.

Novotech is one of only 81 companies that have held this award continually since 2023. Employers aiming to achieve the certification must demonstrate what they are doing to close their own gender pay gap, and through employee consultation, create policies and strategies to prevent sex-based harassment and discrimination, while setting targets for improving gender equality outcomes. They must account for their progress every two years.

Dr. John Moller, CEO of Novotech stated: "Receiving this re-certification in 2024 is a testament to our unwavering dedication to diversity and inclusion. It reflects the collective effort of our entire organization to champion these values. As we expand globally, we're committed to extending these best practices across all our operations, aiming to inspire positive change throughout our industry."

Angela Edwardson, Chief People Officer of Novotech added: "Our journey towards gender equality is an ongoing process deeply embedded in our corporate culture. The initiatives we've implemented as a WGEA Employer of Choice are not just policies on paper; they shape our daily operations, influence our strategic decisions, and contribute to a workplace environment that nurtures talent irrespective of gender."

Mary Wooldridge, CEO of WGEA: “In taking action to improve gender equality, EOCGE employers unlock enormous benefits for their business. Employees are more likely to join and to stay in organizations that prioritize a culture of equality and inclusion. Research also shows that businesses with greater gender balance in leadership roles are more profitable and productive.”

Novotech stands out among the select group of Australian employers in maintaining this prestigious citation, showcasing its sustained commitment to gender equality. As the company continues to grow and evolve, its dedication to creating an inclusive, diverse, and equitable workplace remains at the forefront of its organizational values, positively impacting the lives and careers of our employees.

The WGEA Employer of Choice for Gender Equality citation reaffirms Novotech's position as a leader in workplace equality. It not only sets a benchmark for the biotech and CRO sectors in Australia and internationally but also inspires others to follow suit, making us all proud to be a leader of this positive change in our industry.

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

Background: The WGEA EOCGE citation

Criteria for the citation cover leadership, learning and development, gender pay gaps, flexible working and other initiatives to support family responsibilities.

The criteria also ask employers about employee consultation, policies and strategies to prevent sex-based harassment and discrimination, and targets for improving gender equality outcomes.

Employers must demonstrate what they are doing to close their own gender pay gap by conducting an annual analysis of what’s driving their gender pay gap and following up on this by setting targets and identifying actions to reduce it. They must account for their progress every 2 years.

The Agency’s certification process also requires employee confirmation that there’s a zero-tolerance approach to gender-based harassment and sexual harassment, and that managers genuinely create environments within their teams that support equality for all employees.

The criteria are regularly strengthened to reflect best practice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240826774489/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release

Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse

Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye